878396-94-2

Upstream product

• 111-29-5 1 ,5-pentanediol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 121671-76-9 5-(tert-butyldiphenylsilyloxy)pentan-1-ol 
• 5259-98-3 5-chloropentan-1-ol 

Downstream Products

• 878396-89-5 N,N'-bis(2-nitrobenzenesulfonyl)-N,N'-bis-[5-(tert-butyldiphenylsilanyloxy)pentyl]butane-1,4-diamine 
• 878396-88-4 N,N'-bis(2-nitrobenzenesulfonyl)-N,N'-bis-[5-(tert-butyldiphenylsilanyloxy)pentyl]ethane-1,2-diamine 
• 878396-91-9 N,N'-bis-[5-(tert-butyldiphenylsilanyloxy)pentyl]butane-1,4-diamine 
• 878396-90-8 N,N'-bis-[5-(tert-butyldiphenylsilanyloxy)pentyl]ethane-1,2-diamine 
• 164025-54-1 tert-butyl-(5-iodo-pentyloxy)-diphenyl-silane 

Relevant academic research and scientific papers

Rotaxanes of cyclic peptides

The synthesis of rotaxanes derived from the synthetic peptide macrocycles cyclo(l-ProGly)4 and cyclo(l-ProGly)5 and diammonium threads is described. [2]Rotaxanes are formed in good yields (56-63%), despite the disruption of internal

Catalytic phosphorus(V)-mediated nucleophilic substitution reactions: Development of a catalytic appel reaction

Catalytic phosphorus(V)-mediated chlorination and bromination reactions of alcohols have been developed. The new reactions constitute a catalytic version of the classical Appel halogenation reaction. In these new reactions oxalyl chloride is used as a consumable stoichiometric reagent to generate the halophosphonium salts responsible for halogenation from catalytic phosphine oxides. Thus, phosphine oxides have been transformed from stoichiometric waste products into catalysts and a new concept for catalytic phosphorus-based activation and nucleophilic substitution of alcohols has been validated. The present study has focused on a full exploration of the scope and limitations of phosphine oxide catalyzed chlorination reactions as well as the development of the analogous bromination reactions. Further mechanistic studies, including density functional theory calculations on proposed intermediates of the catalytic cycle, are consistent with a catalytic cycle involving halo- and alkoxyphosphonium salts as intermediates.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.